COPD Assessment Test (CAT) is a Valid and Simple Tool to Measure the Impact of Bronchiectasis on Affected Patients

Autor: Simone Dal Corso, Rafael Stelmach, Rejane Agnelo Silva de Castro, Fernanda de Cordoba Lanza, Samia Zahi Rached, Anderson Alves de Camargo, Drielly Jesica Milani Zanatta, Alberto Cukier, Rodrigo Abensur Athanazio
Rok vydání: 2018
Předmět:
Male
Vital Capacity
Severity of Illness Index
Hospitals
University
Tertiary Care Centers
Pulmonary Disease
Chronic Obstructive
0302 clinical medicine
Quality of life
Bronquiectasia
Forced Expiratory Volume
Surveys and Questionnaires
Doença pulmonar obstrutiva crônica
Activities of Daily Living
Respiratory function
Routine clinical practice
030212 general & internal medicine
COPD
Middle Aged
Test (assessment)
Bronchiectasis
Female
Health Impact Assessment
Brazil
Pulmonary and Respiratory Medicine
Adult
medicine.medical_specialty
Walk Test
Statistics
Nonparametric
03 medical and health sciences
Qualidade de vida
medicine
Humans
Analysis of Variance
Tosse
business.industry
Reproducibility of Results
medicine.disease
Cross-Sectional Studies
Dyspnea
030228 respiratory system
Cough
Spirometry
Physical therapy
Copd assessment test
Exercise Test
Quality of Life
business
Respiração - Medição
Zdroj: Repositório Institucional da UFMG
Universidade Federal de Minas Gerais (UFMG)
instacron:UFMG
ISSN: 1541-2563
Popis: FAPESP - Fundação de Amparo à Pesquisa do Estado de São Paulo The COPD assessment test (CAT) is a short questionnaire developed to help patients and clinicians to assess the impact of symptoms in routine clinical practice. We aimed to validate and to test the reproducibility of CAT in patients with bronchiectasis and correlate with the severity of dyspnea, aerobic and functional capacity, and physical activity in daily life. This is a cross-sectional study, patients with bronchiectasis underwent spirometry, cardiopulmonary exercise test (CPET), incremental shuttle walk test (ISWT), Saint George`s Respiratory Questionnaire (SGRQ), and received pedometer. CAT was applied twice (CAT-1 and CAT-2, 7 to 10 days apart). The severity of bronchiectasis was assessed by E-FACED and bronchiectasis severity index (BSI). A total of 100 patients were evaluated (48 ± 14 years, 59 women, FVC: 67 ± 22% pred, FEV1: 52 ± 25% pred). According to CAT, 14% patients presented low, 40% medium, 32% high, and 14% very high impact. The higher the CAT, the worse the severity of bronchiectasis, dyspnea, quality of life, performance on the CPET, and smaller the distance walked (DW) on the ISWT and number of steps (NS) per day. There was significant correlation between CAT and SGRQ, E-FACED, BSI, NS, ISWT, oxygen uptake, and workload at CPET. CAT-1 and CAT-2 presented similar values: 21 (13–26) and 19 (13–26), respectively. The CAT is a valid and reproducible instrument in patients with bronchiectasis presenting good correlation with clinical, functional, and quality of life measurements. This easy-to-use, easy-to-understand, quick, and useful tool may play an important role to assess the impact of bronchiectasis on both daily medical practice and clinical trial settings.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje